T.Rx Capital

T.Rx Capital

T.Rx Capital was formed by a quartet of scientist-operators who bridge academic research, Big Pharma dealmaking, and startup creation. Executive Chairman Robert Langer has co-founded more than 40 biotech companies, including Moderna and Alnylam. Managing Partner Kwesi Frimpong-Boateng arrived from the immunology strategy group at Eli Lilly, where he executed licensing deals with Sitryx and Rigel. Corey McCann built and took Pear Therapeutics public as the first FDA-approved digital-therapeutics company. Michael Langer complements the trio with a venture track record from his prior firm, Old Silver VC, and operating experience at Pear. The firm runs out of Boston, positioning it squarely within the Cambridge-MIT biotech corridor. The firm deploys capital exclusively at the seed stage, targeting companies at the intersection of technology and biology. Its strategy spans novel drug modalities, medical devices, diagnostics, and healthcare software. T.Rx Capital announced the close of its inaugural fund, T.Rx Fund 1, a vehicle designed to back founders reimagining healthcare delivery and therapeutic development. Confirmed portfolio companies include Recuro, an integrated digital-health platform, Zus, a health-data interoperability company, and a stealth-stage radiopharmaceuticals firm. The team also founded a NewCo targeting intractable pain conditions. The geographic focus draws from the US biotech hubs, with Principal Pranav Seshadri additionally maintaining a board role at the Sena Institute of Technology Foundation in Ghana, which hints at an emerging cross-border scientific network. The team lists nine named professionals, including Venture Partners Dr. Liz Kwo, who serves on the board of Walmart Mexico and Central America, and Dr. Debbie Lin, concurrently VP at Caris Life Sciences. An advisory board stacks former Pfizer Chief Medical Officer Freda Lewis-Hall, Third Rock Ventures founder Mark Levin, Boston Scientific co-founder John Abele, and former Biogen R&D head Alfred Sandrock. The firm maintains a fractional operating model for non-investment roles — Dan O'Neill serves as Fractional COO while running his own IT services firm. In mid-2026, T.Rx Capital lists T.Rx Fund 1 as closed and actively deploying into early-stage healthcare, though the firm does not disclose fund size or total AUM. T.Rx Capital's structural edge lies in combining a principal who holds the highest H-index of any engineer in history (Robert Langer) with partners who have operated at both venture capital firms and operating companies. The Langer lab at MIT — the world's largest biomedical engineering lab — provides a proprietary origination funnel that few other seed-stage healthcare managers can replicate. The advisory board includes the former Chief Counsel of the FDA, the founder of Third Rock Ventures and an original co-inventor of the drug-eluting stent. That constellation positions the firm to diligence, de-risk, and champion regulatory-sensitive therapeutics companies from the earliest formation stage.